

# CV Sciences Certificate of Analysis



*This document is to certify that units of the lot number below were tested and found to comply with CV Sciences finished product specifications.*

**SAMPLE ID:**

**PRODUCT NAME:**

Strength:

Lot Number:

Expiration Date:

**CANNABINOIDS\***

**MG/UNIT**

**METHOD**

CBD

CBDA

d9-THC

THCA-A

d8-THC

THCV

CBDV

CBDVA

CBGA

CBG

CBN

CBC

CBL

Total Cannabinoids

Sample Size

THC by Mass

**OTHER ACTIVE INGREDIENTS**

**MG/UNIT**

**METHOD**

Lemon Balm Extract

Magnolia Extract

Melatonin \*\*\*

**HEAVY METALS\***

**STATUS (PASS/FAIL)**

**METHOD**

Arsenic

Cadmium

Mercury

Lead

# CV Sciences Certificate of Analysis



MICROBIOLOGY*	STATUS (PASS/FAIL)	METHOD
Mold/Mildew/Yeast		
Aerobic Bacteria		
Coliforms		
E. Coli		
Salmonella		
Pseudomonas		

PESTICIDES**	STATUS (PASS/FAIL)	METHOD
Total Pesticides		

RESIDUAL SOLVENTS**	STATUS (PASS/FAIL)	METHOD
Total Residual Solvents		

1. The hemp extract is the product of a batch tested by the independent testing laboratory;
2. The batch contained a total delta-9-tetrahydrocannabinol concentration that did not exceed 0.3 percent pursuant to the testing of random sample of the batch; and
3. The batch does not contain contaminants unsafe for human consumption.†

†Tested analytes and limits were set by CV Sciences, Inc.

DB Labs Sample ID #:

\*Actual analytical results obtained by DB Labs (Las Vegas, NV), CV Sciences' third-party testing laboratory.

Anresco Laboratories Sample ID #:

\*\*Actual analytical results obtained by Anresco Laboratories (San Francisco, CA), CV Sciences' third-party testing laboratory.

## QUALITY APPROVAL

Prepared By / Date

Approved By / Date

Status

Vandana Kothari

DocuSigned by Vandana Kothari  
  
 I approve this document  
 03-Jan-2024 | 09:17 PST  
 87A410FFF032487389008EED0868E359



January 02, 2024

**CV SCIENCES, INC.**9530 Padgett Street, Suite 107  
San Diego, CA 92126Order No. 551454  
Sample No. 1186953**SAMPLE INFORMATION**

**Description** Plus CBD Sleep Gummies  
**Lot Number** A106251223  
**Category (Type)** Non-Inhalable Edible (Gummy)  
**Received** December 29, 2023

**ANALYTICAL RESULTS**

**Analysis** Cannabinoid Profile ✔ Pass  
**Instrument** Liquid Chromatography Diode Array Detector (LC-DAD)  
**Method** MF-CHEM-15  
**Analysis Date** December 29, 2023 to January 02, 2024

Cannabinoid	mg/g	%	mg/serving	mg/package	Labeled mg/ serving	% Difference (mg/ serving)	Status
Δ8-THC	ND	ND	ND	ND	-	-	-
Δ9-THC	ND	ND	ND	ND	-	-	Pass
Δ9-THCA	ND	ND	ND	ND	-	-	-
THCV	ND	ND	ND	ND	-	-	-
THCVA	ND	ND	ND	ND	-	-	-
CBD	3.07	0.307	12.51	750.53	10	25.09	-
CBDA	ND	ND	ND	ND	-	-	-
CBC	ND	ND	ND	ND	-	-	-
CBCA	ND	ND	ND	ND	-	-	-
CBDV	ND	ND	ND	ND	-	-	-
CBG	ND	ND	ND	ND	-	-	-
CBGA	ND	ND	ND	ND	-	-	-
CBN	ND	ND	ND	ND	-	-	-
Total THC	ND	ND	ND	ND	-	-	-
Total CBD	3.07	0.307	12.51	750.53	-	-	-
Total Cannabinoids	3.07	0.307	12.51	750.53	-	-	-
Sum of Cannabinoids	3.07	0.307	12.51	750.53	-	-	-
<b>Serving Weight (g)</b>	4.0768						
<b>Package Weight (g)</b>	244.61						

**Comments**

This result of this sample is confirmed with a retest.

Reported by  
**Anresco, Inc.**

Limit of Detection: 0.033 mg/g  
 Limit of Quantitation: 0.1 mg/g  
 ND = None Detected  
 <LOQ = Below Limit of Quantitation  
 LOD = Limit of Detection  
 Total THC = Δ9-THC + (0.877 \* Δ9-THCA)  
 Total CBD = CBD + (0.877 \* CBDA)  
 Total Cannabinoids = Σ (neutral cannabinoids) + [0.877 \* Σ (acidic cannabinoids)]



January 02, 2024

If there are any questions with this report, please contact "[compliance@anresco.com](mailto:compliance@anresco.com)".

January 02, 2024

**CV SCIENCES, INC.**

9530 Padgett Street, Suite 107  
 San Diego, CA 92126

Order No. 551454  
 Sample No. 1186953

## SAMPLE INFORMATION

**Description** Plus CBD Sleep Gummies  
**Lot Number** A106251223  
**Category (Type)** Non-Inhalable Edible (Gummy)  
**Received** December 29, 2023

## ANALYTICAL RESULTS

**Analysis** Residual Solvent Screen ✔ Pass  
**Instrument** Gas Chromatography Mass Spectrometry (GC/MS)  
**Method** MF-CHEM-32  
**Analysis Date** December 29, 2023 to January 02, 2024

Analyte	LOD/LOQ (ppm)	Findings (ppm)	Limit (ppm)	Status
1,2-Dichloroethane	0.2/0.5	ND	1	Pass
Acetone	67/200	ND	5000	Pass
Acetonitrile	67/200	ND	410	Pass
Benzene	0.2/0.5	ND	1	Pass
n-Butane	67/200	ND	5000	Pass
Chloroform	0.2/0.5	ND	1	Pass
Ethanol	67/200	ND	5000	Pass
Ethyl acetate	67/200	ND	5000	Pass
Ethyl ether	67/200	ND	5000	Pass
Ethylene oxide	0.2/0.5	ND	1	Pass
n-Heptane	67/200	ND	5000	Pass
n-Hexane	67/200	ND	290	Pass
Isopropyl alcohol	67/200	ND	5000	Pass
Methanol	67/200	ND	3000	Pass
Methylene chloride	0.2/0.5	ND	1	Pass
n-Pentane	67/200	ND	5000	Pass
Propane	67/200	ND	5000	Pass
Toluene	67/200	ND	890	Pass
Total xylenes (ortho-, meta-, para-)	67/200	ND	2170	Pass
Trichloroethylene	0.2/0.5	ND	1	Pass

Reported by  
**Anresco, Inc.**

ND = None Detected

  
 Alma Dorantes  
 Analyst I



January 02, 2024

If there are any questions with this report, please contact "[compliance@anresco.com](mailto:compliance@anresco.com)".

January 02, 2024

**CV SCIENCES, INC.**  
9530 Padgett Street, Suite 107  
San Diego, CA 92126Order No. 551454  
Sample No. 1186953

## SAMPLE INFORMATION

**Description** Plus CBD Sleep Gummies  
**Lot Number** A106251223  
**Category (Type)** Non-Inhalable Edible (Gummy)  
**Received** December 29, 2023

## ANALYTICAL RESULTS

**Analysis** Heavy Metals ✔ Pass  
**Instrument** Inductively Coupled Plasma Mass Spectrometry (ICP-MS)  
**Method** MF-CHEM-16  
**Analysis Date** December 29, 2023 to January 02, 2024

Analyte	LOD/LOQ (µg/g)	Findings (µg/g)	Limit (µg/g)	Status
Arsenic	0.02/0.05	ND	1.5	Pass
Cadmium	0.02/0.05	ND	0.5	Pass
Mercury	0.02/0.05	ND	3	Pass
Lead	0.02/0.05	BLOQ	0.5	Pass

Reported by  
**Anresco, Inc.**

ND = None Detected



Eric Tam  
Senior Chemist

January 02, 2024

If there are any questions with this report, please contact "[compliance@anresco.com](mailto:compliance@anresco.com)".

January 02, 2024

**CV SCIENCES, INC.**

9530 Padgett Street, Suite 107  
 San Diego, CA 92126

Order No. 551454  
 Sample No. 1186953

## SAMPLE INFORMATION


**Description** Plus CBD Sleep Gummies  
**Lot Number** A106251223  
**Received** December 29, 2023


## ANALYTICAL RESULTS

**Analysis Date** December 29, 2023 to January 02, 2024

Findings	Analysis	Results	Method
	Salmonella	Negative/25g	AOAC 2016.01
	STEC	Negative/25g	3M MDS STEC

Reported by  
**Anresco, Inc.**

  
 Jessica Lingua  
 Analyst



If there are any questions with this report, please contact "[compliance@anresco.com](mailto:compliance@anresco.com)".

page 1 of 1

January 02, 2024

**CV SCIENCES, INC.**

9530 Padgett Street, Suite 107  
 San Diego, CA 92126

Order No. 551454  
 Sample No. 1186953

## SAMPLE INFORMATION

**Description** Plus CBD Sleep Gummies  
**Lot Number** A106251223  
**Category (Type)** Non-Inhalable Edible (Gummy)  
**Received** December 29, 2023

## ANALYTICAL RESULTS

**Analysis** Pesticides Screen ✔ Pass  
**Instrument** Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) & Gas Chromatography Tandem Mass Spectrometry (GC-MS/MS)  
**Method** MF-CHEM-13  
**Analysis Date** December 29, 2023 to January 02, 2024

Analyte	LOD/LOQ (µg/g)	Findings (µg/g)	Limit (µg/g)	Status
Abamectin	0.04/0.10	ND	0.3	Pass
Acephate	0.02/0.06	ND	5.0	Pass
Acequinocyl	0.04/0.10	ND	4.0	Pass
Acetamiprid	0.02/0.06	ND	5.0	Pass
Aldicarb	0.02/0.06	ND	0.02	Pass
Azoxystrobin	0.02/0.06	ND	40.0	Pass
Bifenazate	0.02/0.06	ND	5.0	Pass
Bifenthrin	0.04/0.10	ND	0.5	Pass
Boscalid	0.02/0.06	ND	10.0	Pass
Captan	0.2/0.6	ND	5.0	Pass
Carbaryl	0.02/0.06	ND	0.5	Pass
Carbofuran	0.02/0.06	ND	0.02	Pass
Chlorantraniliprole	0.02/0.06	ND	40.0	Pass
Chlordane	0.02/0.06	ND	0.02	Pass
Chlorfenapyr	0.02/0.08	ND	0.02	Pass
Chlorpyrifos	0.02/0.06	ND	0.02	Pass
Clofentezine	0.02/0.06	ND	0.5	Pass
Coumaphos	0.02/0.06	ND	0.02	Pass
Cyfluthrin	0.10/0.30	ND	1.0	Pass
Cypermethrin	0.10/0.30	ND	1.0	Pass
Daminozide	0.02/0.06	ND	0.02	Pass
DDVP (Dichlorvos)	0.02/0.06	ND	0.02	Pass
Diazinon	0.02/0.06	ND	0.2	Pass
Dimethoate	0.02/0.06	ND	0.02	Pass
Dimethomorph	0.02/0.06	ND	20.0	Pass
Ethoprop(hos)	0.02/0.06	ND	0.02	Pass
Etofenprox	0.02/0.06	ND	0.02	Pass
Etoxazole	0.02/0.06	ND	1.5	Pass
Fenhexamid	0.02/0.06	ND	10.0	Pass
Fenoxycarb	0.02/0.06	ND	0.02	Pass
Fenpyroximate	0.02/0.06	ND	2.0	Pass

If there are any questions with this report, please contact "[compliance@anresco.com](mailto:compliance@anresco.com)".

Analyte	LOD/LOQ (µg/g)	Findings (µg/g)	Limit (µg/g)	Status
Fipronil	0.02/0.06	ND	0.02	Pass
Flonicamid	0.02/0.06	ND	2.0	Pass
Fludioxonil	0.02/0.06	ND	30.0	Pass
Hexythiazox	0.02/0.06	ND	2.0	Pass
Imazalil	0.02/0.06	ND	0.02	Pass
Imidacloprid	0.02/0.06	ND	3.0	Pass
Kresoxim Methyl	0.02/0.06	ND	1.0	Pass
Malathion	0.02/0.06	ND	5.0	Pass
Metalaxyl	0.02/0.06	ND	15.0	Pass
Methiocarb	0.02/0.06	ND	0.02	Pass
Methomyl	0.02/0.06	ND	0.1	Pass
Methyl parathion	0.02/0.06	ND	0.02	Pass
Mevinphos	0.02/0.06	ND	0.02	Pass
Myclobutanil	0.02/0.06	ND	9.0	Pass
Naled	0.02/0.06	ND	0.5	Pass
Oxamyl	0.02/0.06	ND	0.2	Pass
Pacllobutrazol	0.02/0.06	ND	0.02	Pass
Pentachloronitrobenzene	0.04/0.10	ND	0.2	Pass
Permethrins	0.10/0.30	ND	20.0	Pass
Phosmet	0.02/0.06	ND	0.2	Pass
Piperonyl Butoxide	0.02/0.06	ND	8.0	Pass
Prallethrin	0.04/0.10	ND	0.4	Pass
Propiconazole	0.02/0.06	ND	20.0	Pass
Propoxur	0.02/0.06	ND	0.02	Pass
Pyrethrins	0.15/0.50	ND	1.0	Pass
Pyridaben	0.02/0.06	ND	3.0	Pass
Spinetoram	0.02/0.06	ND	3.0	Pass
Spinosad	0.02/0.06	ND	3.0	Pass
Spiromesifen	0.04/0.10	ND	12.0	Pass
Spirotetramat	0.02/0.06	ND	13.0	Pass
Spiroxamine	0.02/0.06	ND	0.02	Pass
Tebuconazole	0.02/0.06	ND	2.0	Pass
Thiacloprid	0.02/0.06	ND	0.02	Pass
Thiamethoxam	0.02/0.06	ND	4.5	Pass
Trifloxystrobin	0.02/0.06	ND	30.0	Pass

Reported by  
**Anresco, Inc.**

ND = None Detected



Alda Tan  
 Analyst II

January 02, 2024

If there are any questions with this report, please contact "[compliance@anresco.com](mailto:compliance@anresco.com)".



## ANALYTICAL RESULTS

**Analysis** Mycotoxins Screen ✔ Pass  
**Instrument** Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) & Gas Chromatography Tandem Mass Spectrometry (GC-MS/MS)  
**Method** MF-CHEM-13  
**Analysis Date** December 29, 2023 to January 02, 2024

Analyte	LOD/LOQ (µg/kg)	Findings (µg/kg)	Limit (µg/kg)	Status
Aflatoxin B1	2/5	ND	-	-
Aflatoxin B2	2/5	ND	-	-
Aflatoxin G1	2/5	ND	-	-
Aflatoxin G2	2/5	ND	-	-
Total Aflatoxins	8/20	ND	20	Pass
Ochratoxin A	6/18	ND	20	Pass

Reported by  
**Anresco, Inc.**

ND = None Detected



Alda Tan  
Analyst II

January 02, 2024

If there are any questions with this report, please contact "[compliance@anresco.com](mailto:compliance@anresco.com)".

January 02, 2024

**CV SCIENCES, INC.**  
9530 Padgett Street, Suite 107  
San Diego, CA 92126

Order No. 551454  
Sample No. 1186953

## SAMPLE INFORMATION

Description	Plus CBD Sleep Gummies
Lot Number	A106251223
Category (Type)	Non-Inhalable Edible (Gummy)
Received	December 29, 2023

## ANALYTICAL RESULTS

Analysis	Melatonin
Instrument	HPLC-DAD/FLD
Method	USP42-NF37 - Melatonin (5085)
Analysis Date	December 29, 2023 to January 02, 2024

Analyte	Findings (mg/gummy)
Melatonin	4.22

Reported by  
**Anresco, Inc.**

ND = None Detected



Cathy Cheng  
Senior Analyst

January 02, 2024

If there are any questions with this report, please contact "[compliance@anresco.com](mailto:compliance@anresco.com)".


**Certificate Of Completion**

Envelope Id: DF6531EE665B42359A6B1496BB71879E	Status: Completed
Subject: FP-23-0150 pluscbd 60ct Sleep Gummy sku 606 exp 12/25 A106251223 coa	
Source Envelope:	
Document Pages: 10	Signatures: 1
Certificate Pages: 1	Initials: 0
AutoNav: Enabled	Envelope Originator:
Envelopeld Stamping: Enabled	Vandana Kothari
Time Zone: (UTC-08:00) Pacific Time (US & Canada)	vandana.kothari@cvsciences.com
	IP Address: 162.248.186.11

**Record Tracking**

Status: Original	Holder: Vandana Kothari	Location: DocuSign
1/3/2024 9:15:21 AM	vandana.kothari@cvsciences.com	

**Signer Events**

Signer Events	Signature	Timestamp
Vandana Kothari vandana.kothari@cvsciences.com DIRECTOR OF QUALITY CV Sciences - Part 11 Security Level: Email, Account Authentication (Required)	  Signature Adoption: Pre-selected Style Signature ID: 87A410FF-F032-4873-8900-BEED0868E359 Using IP Address: 75.85.176.253  With Signing Authentication via DocuSign password With Signing Reasons (on each tab): I approve this document	Sent: 1/3/2024 9:16:10 AM Viewed: 1/3/2024 9:17:08 AM Signed: 1/3/2024 9:17:36 AM

**Electronic Record and Signature Disclosure:**  
Not Offered via DocuSign

**In Person Signer Events**

Signature	Timestamp
-----------	-----------

**Editor Delivery Events**

Status	Timestamp
--------	-----------

**Agent Delivery Events**

Status	Timestamp
--------	-----------

**Intermediary Delivery Events**

Status	Timestamp
--------	-----------

**Certified Delivery Events**

Status	Timestamp
--------	-----------

**Carbon Copy Events**

Status	Timestamp
--------	-----------

**Witness Events**

Signature	Timestamp
-----------	-----------

**Notary Events**

Signature	Timestamp
-----------	-----------

**Envelope Summary Events**

Status	Timestamps
Envelope Sent	Hashed/Encrypted 1/3/2024 9:16:10 AM
Certified Delivered	Security Checked 1/3/2024 9:17:08 AM
Signing Complete	Security Checked 1/3/2024 9:17:36 AM
Completed	Security Checked 1/3/2024 9:17:36 AM

**Payment Events**

Status	Timestamps
--------	------------